Boston, MA – According to filings with the U.S. Securities and Exchange Commission, EIP Pharma is raising $10,000,000.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, Noel Donnelly played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About EIP Pharma

EIP Pharma is a clinical stage therapeutics company dedicated to the development and commercialization of drug treatments for neurodegenerative diseases with a focus on the early stages of the neurodegenerative process. We have assembled a highly experienced executive management team led by our two co-founders, board of directors and scientific advisory board to execute on our mission to develop and commercialize innovative drug treatments for Alzheimer’s disease and other central nervous system disorders. Our management team is led by our Co-Founders, John Alam, MD and Sylvie GrΘgoire, PharmD.

To learn more about EIP Pharma, visit http://www.eippharma.com/

Contact:
Noel Donnelly, Chief Financial Officer
617-744-4400
ndonnelly@eippharma.com
https://www.linkedin.com/in/noel-donnelly-6b6093a/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved